Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

32P-therapy in polycythemia vera

G Meuret, G Hoffmann, R Gmelin

    Klinische Wochenschrift
    |June 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Radioactive phosphorus (32P) therapy effectively treated polycythemia vera, inducing remissions in all patients. Long-term treatment showed a mean survival of 12 years, with a low incidence of acute leukemia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Combined IMIG and immune Ig attenuates inflammatory colitis in mice.

    International immunopharmacology·2020
    Same author

    Opinion paper: Measuring livestock robustness and resilience: are we on the right track?

    Animal : an international journal of animal bioscience·2020
    Same author

    Mechanism(s) of prolonged attenuation of allergic responses after modulation of idiotypic regulatory network.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2019
    Same author

    Technical note: Development of a noninvasive respiration rate sensor for cattle.

    Journal of dairy science·2018
    Same author

    BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

    Breast cancer research and treatment·2017
    Same author

    [Safe treatment of acute hyperkalemia : The 1:4 and other principles].

    Der Anaesthesist·2017
    Same journal

    Klinische Wochenschrift·2020
    Same journal

    Pathological anatomy of malnutrition.

    Klinische Wochenschrift·2010
    Same journal

    Consequences of chronic malnutrition in the clinical picture of internal diseases.

    Klinische Wochenschrift·2010
    Same journal

    Use of stable isotopes in biology.

    Klinische Wochenschrift·2010
    Same journal

    About applications of radioactive indicators in medicine and physiology.

    Klinische Wochenschrift·2010
    Same journal

    Early diagnosis and assessment of the activity of pulmonary tuberculosis based on serological examinations.

    Klinische Wochenschrift·2010
    See all related articles

    Area of Science:

    • Hematology
    • Nuclear Medicine
    • Oncology

    Background:

    • Polycythemia vera is a chronic myeloproliferative neoplasm characterized by excessive red blood cell production.
    • Long-term management strategies are crucial for improving patient outcomes and quality of life.
    • Radioactive phosphorus (32P) has been utilized as a therapeutic agent in managing polycythemia vera.

    Purpose of the Study:

    • To evaluate the long-term efficacy and safety of radioactive phosphorus (32P) therapy in patients with polycythemia vera.
    • To assess remission rates, duration of remission, and survival outcomes.
    • To investigate the correlation between spleen size and remission time.

    Main Methods:

    • A cohort of 52 consecutive patients with polycythemia vera received long-term therapy with 32P.

    Related Experiment Videos

  • Treatment involved an initial phase and maintenance therapy.
  • Hematological parameters, spleen size, remission status, and survival data were monitored.

    • Main Results:

    • Initial 32P therapy induced complete remissions in 45% and partial remissions in 55% of patients.
    • Mean remission time was approximately 3.5 years for complete remissions, with individual durations ranging from 1 to 6 years.
    • Mean survival time, considering polycythemia-related deaths, reached 12 years post-treatment; acute leukemia occurred in 4% of patients.

    Conclusions:

    • Long-term radioactive phosphorus (32P) therapy is an effective treatment for polycythemia vera, achieving significant remission rates.
    • The therapy demonstrates a favorable long-term survival benefit for patients with polycythemia vera.
    • Spleen size is a negative prognostic factor influencing remission duration in patients with splenomegaly.